Genmab — August 2013
-
The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone (n = 64). Time to retreatment also appeared longer for ofatumumab-based CIT (free of retreatment at 24 months: 86% [95% confidence interval = 75-99] versus 68% [95% confidence interval = 56-81] for rituximab-based CIT).
-
-
det er da vildt gode news
-
nej og man må sige at markedet ikke har høje tanker om at arzerra er på vej mod at blive en seriøs konkurrent mod rituxian
-
-
http://www.evaluategroup.com/Universal/View.aspx?type=Report&id={8C80816D-658A-4085-BA10-B579001800B0}¶ms=<PARAMS currencyId="0"><PARAM linkKind="1" name="abio 05/01" /></PARAMS>&more=true#&&_ViewArgs=%7b%22_EntityType%22%3a0%2c%22_Parameters%22%3a%7b%22_ContextData%22%3a%22%7b%5c%22isEPVantage%5c%22%3atrue%2c%5c%22percentage%5c%22%3a-1%2c%5c%22searchWords%5c%22%3a%5c%22%5c%22%2c%5c%22sectionID%5c%22%3a%5c%22%5c%22%2c%5c%22storyID%5c%22%3a%5c%22450132%5c%22%2c%5c%22notSub%5c%22%3afalse%7d%22
-
ikke rigitigt, men det gør dagens milestone meddelelse
-
-
“Janssen thinks [dara] will be very big – they describe it as potentially the new backbone treatment for multiple myeloma in all lines of therapy,” Mr van de Winkel says.
-
Mr van de Winkel describes dara as “the most potent naked antibody I have seen in my 25 years of antibody development”,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind